New drug combo aims to outsmart lymphoma resistance
NCT ID NCT07717580
First seen Jul 21, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This phase II trial tests whether adding lisaftoclax to brentuximab vedotin improves outcomes for people with CD30-positive cutaneous T-cell lymphoma, including mycosis fungoides and primary cutaneous anaplastic large cell lymphoma. About 46 participants are randomly assigned to receive either brentuximab alone or brentuximab plus lisaftoclax. The study measures how many patients respond to treatment and tracks side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin combined with lisaftoclax
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with CD30-positive cutaneous T-cell lymphoma, potentially overcoming resistance to standard therapy.
- What could go wrong
- This is a small, early-phase trial with only 46 participants, so results may not apply broadly. Adding lisaftoclax also carries risks like tumor lysis syndrome, which requires careful dose management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA/MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads skin biopsies to spot hidden lymphomas
- Massive T-Cell lymphoma database aims to unlock new insights
- Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
- Vitamin d boost may extend life in lymphoma patients, trial hopes
- Researchers dig into Real-World data to see how CTCL is actually treated
- New hope for rare lymphoma: targeted drug shows promise in small trial